Cutaneous Lymphoma and Antibody-Directed Therapies

Area of Science:

• Onco-hematology
• Dermato-oncology
• Immunotherapy

Background:

• Monoclonal antibodies (e.g., rituximab) have improved cancer therapy but face challenges with efficacy and resistance.
• Primary cutaneous lymphomas represent an unmet need in dermato-oncology with limited advanced treatment options.

Purpose of the Study:

• To review antibody-directed therapies for lymphoma, focusing on molecular targets and novel strategies.
• To explore the potential of antibody-drug conjugates and other antibody-based approaches for cutaneous lymphoma management.

Main Methods:

• Review of current understanding of T and B cell lymphomagenesis and molecular alterations.
• Survey of various antibody-directed therapies investigated in lymphoma treatment settings.

Main Results:

• Antibody-drug conjugates (e.g., brentuximab vedotin) provide targeted payload delivery.
• A spectrum of antibody-based strategies including bi-specific antibodies, nanotherapeutics, radioimmunotherapy, and photoimmunotherapy are under investigation.

Conclusions:

• Antibody-drug conjugates and other advanced antibody-directed therapies show promise for managing cutaneous lymphomas.
• Targeting molecular alterations in lymphomagenesis is key for developing future therapeutic strategies.